OKYO Pharma (OKYO) Depreciation & Amortization (CF) (2024 - 2026)

OKYO Pharma (OKYO) has reported Depreciation & Amortization (CF) for 3 consecutive years, with -$743.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) changed N/A year-over-year to -$743.0 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 52.92% decrease from a year earlier, with the FY2026 full-year figure at $1.8 billion, down 28.99% from the prior year.
• Depreciation & Amortization (CF) was -$743.0 million for Q1 2026 at OKYO Pharma, down from $2.6 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.9 billion in Q4 2024 and troughed at -$743.0 million in Q1 2026.
• A 3-year average of $1.9 billion and a median of $2.6 billion in 2025 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 33.7% in 2025, down 33.7% in 2025.
• Over 3 years, Depreciation & Amortization (CF) stood at $3.9 billion in 2024, then plunged by 33.7% to $2.6 billion in 2025, then slumped by 128.99% to -$743.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at -$743.0 million (Q1 2026), $2.6 billion (Q4 2025), and $3.9 billion (Q4 2024), per Business Quant data.